Efficacy and safety of sigliptin combined with metformin in the treatment of abdominal obesity type 2 diabetes mellitus

Objective To analyze the efficacy and safety of combined use of metformin and sitagliptin in the treatment of abdominal obesity type 2 diabetes mellitus. Methods Ninety-two abdominal obesity type 2 diabetes melitus patients admitted to Xinxiang First People’s Hospital from January 2018 to January 2019 were selected, and they were divided into observation group and control group by the random number table method, with 46 cases in each group. The control group was treated with metformin on the basis of routine treatment, while the observation group was treated with metformin and ceglistine on the basis of routine treatment. The changes of blood glucose and blood lipids before and after treatment, and the occurrence of adverse reactions were compared between the two groups. Results Before treatment, there was no significant difference in blood glucose related indicators between the two groups (P>0.05). After treatment, the levels of fasting blood glucose , glycosylated hemoglobin and postprandial 2-hour blood glucose (2 h PG) in the observation group were significantly lower than those in the control group (P 0.05). In comparison to preoperative indexes the levels of total cholesterol, triglyceride, low density lipoprotein cholesterol and BMI in the two groups decreased after treatment, and the decrease in the observation group was better than that in the control group (P 0.05). Conclusions The efficacy and safety of metformin and sitagliptin in patients with abdominal obesity type 2 diabetes mellitus are superior. Key words: Type 2 diabetes mellitus; Abdominal obesity; Metformin; Sitagliptin